Literature DB >> 7780591

Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.

A Sparreboom1, O van Tellingen, W J Nooijen, J H Beijnen.   

Abstract

We have developed and validated a sensitive and selective assay for the quantification of paclitaxel and its metabolites 6 alpha, 3'-p-dihydroxypaclitaxel, 3'-p-hydroxypaclitaxel and 6 alpha-hydroxypaclitaxel in plasma, tissue, urine and faeces specimens of mice. Tissue and faeces were homogenized (approximately 0.1-0.2 g/ml) in bovine serum albumin (40 g/l) in water, and urine was diluted (1:5, v/v) in blank human plasma. Sample pretreatment involved liquid-liquid extraction of 200-1000 microliters of sample with diethyl ether followed by automated solid-phase extraction using cyano Bond Elut columns. 2'-Methylpaclitaxel was used as internal standard. The overall recovery of the sample pretreatment procedure ranged from 76 to 85%. In plasma, the lower limit of detection (LOD) and the lower limit of quantitation (LLQ) are 15 and 25 ng/ml, respectively, using 200 microliters of sample. In tissues, faeces and urine the LLQs are 25-100 ng/g, 125 ng/g and 25 ng/ml, respectively, using 1000 microliters (faeces: 200 microliters) of homogenized or diluted sample. The concentrations in the various biological matrices, for validation procedures spiked with known amounts of the test compounds, are read from calibration curves constructed in blank human plasma in the range 25-100,000 ng/ml for paclitaxel and 25-500 ng/ml for the metabolites. The accuracy and precision of the assay fall within the generally accepted criteria for bio-analytical assays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780591     DOI: 10.1016/0378-4347(94)00495-q

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  13 in total

1.  Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

Authors:  Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

2.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

3.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice.

Authors:  Joely D Jacobs; Elizabeth A Hopper-Borge
Journal:  J Vis Exp       Date:  2014-10-27       Impact factor: 1.355

5.  Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Authors:  Roos L Oostendorp; T Buckle; G Lambert; J S Garrigue; J H Beijnen; J H M Schellens; O van Tellingen
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

6.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Authors:  A Sparreboom; J van Asperen; U Mayer; A H Schinkel; J W Smit; D K Meijer; P Borst; W J Nooijen; J H Beijnen; O van Tellingen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Authors:  Serena Marchetti; Dick Pluim; Jos H Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-07-31       Impact factor: 3.850

8.  Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer.

Authors:  Wenwu Xiao; Juntao Luo; Teesta Jain; John W Riggs; Harry P Tseng; Paul T Henderson; Simon R Cherry; Douglas Rowland; Kit S Lam
Journal:  Int J Nanomedicine       Date:  2012-03-27

9.  Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery.

Authors:  Yonglu Wang; Xueming Li; Liyao Wang; Yuanlong Xu; Xiaodan Cheng; Ping Wei
Journal:  Int J Nanomedicine       Date:  2011-07-13

10.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Authors:  J van Asperen; O van Tellingen; A Sparreboom; A H Schinkel; P Borst; W J Nooijen; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.